Abstract
Sarcopenia remains largely undiagnosed and undertreated because of the lack of a universally accepted definition, effective ways to measure it, and identification of the outcomes that should guide treatment efficacy. An ever-growing number of clinicians and researchers along with funding and regulatory agencies have gradually recognized that sarcopenia is a human condition that requires both prevention and treatment. In this article, we review sarcopenia and its common and less known pharmacological treatments, attempt to define sarcopenia in its broader context, and present some new ideas for potential future treatment for this devastating condition.
Footnotes
This work was supported by the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases [Grant RC2-AR058962]; the National Institutes of Health National Institute on Aging [Grant 1P01-AG039355-01A1]; and grants from Missouri Life Sciences Research Board and Department of Health Services-Clay County Senior Services (to MB).
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS:
- GH
- growth hormone
- DHEA
- dehydroepiandrosterone
- EPA
- eicosapentaenoic acid
- DHA
- docosahexaenoic acid
- ALA
- α-linolenic acid
- ACE
- angiotensin-converting enzyme
- Myf-5
- myogenic factor 5
- AICAR
- 5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide.
- Received June 26, 2012.
- Accepted August 27, 2012.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
